osteonecrosis Archives - ACR Meeting Abstracts

Abstract Number: 1626 • ACR Convergence 2021
Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
J. Alex Gibbons¹, Cynthia Kahlenberg¹, Deanna Jannat-Khah¹, Susan Goodman¹, Lisa Mandl¹, Peter Sculco¹, Stuart Goodman², Mark Figgie¹ and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Stanford University, Stanford, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total hip arthroplasty (THA) is a treatment option for young patients with severe hip pathology due to congenital, developmental, rheumatologic, traumatic, and other acquired…
Abstract Number: 135 • Pediatric Rheumatology Symposium 2020
Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression
Paivi Miettunen¹, Chloe Stephenson ¹, Seemab Haider ¹, Seamus Stephenson ², Vijay Moorjani ² and Rondald Anderson ², ¹University of Calgary, Calgary, Alberta, Canada, ²University of Calgary, Calgary, Canada
Background/Purpose: Osteonecrosis has emerged as debilitating complication of acute pediatric lymphoblastic leukemia (pALL), with severe pain and poor functional outcome. Patients with ON of weight…
Abstract Number: 1578 • ACR/ARP Annual Meeting 2019
Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ³, ¹University Health Network, University of Toronto, Toronto, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteonecrosis (ON) complicates approximately 15-20% of patients with systemic lupus erythematosus (SLE) on an average of six years after diagnosis. However, a small subgroup…
Abstract Number: 1790 • ACR/ARHP Annual Meeting 2016
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described. We report the annual occurrence of these features in an inception…
Abstract Number: 260 • ACR/ARHP Annual Meeting 2012
Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Marc C. Hochberg¹, Steven B. Abramson², David S. Hungerford³, Edward McCarthy⁴, Eric P. Vignon⁵, Michael D. Smith⁶, Leslie Tive⁷, Kenneth M. Verburg⁶ and Christine R. West⁸, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ³Department of Ortho Surgery, Johns Hopkins University, Baltimore, MD, ⁴Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology 2B, Centre Hospitalier, Pierre Benite, France, ⁶Pfizer, Inc., Groton, CT, ⁷Arthritis, Pfizer Inc, New York, NY, ⁸Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Tanezumab (TNZ) has been shown to be efficacious for pain and function in patients with hip and knee osteoarthritis (OA). Unexpected reports of adverse…

Abstracts tagged "osteonecrosis"

Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis

Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression

Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus

Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort

Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program